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NeuroplasticityFumonisins are mycotoxins that naturally occur as contaminants in grains that are destined for animal and
human consumption. Thesemycotoxins cause hepatotoxic, nephrotoxic, carcinogenic, teratogenic, immunotoxic,
and neurotoxic effects in different intensities based on dose, time of exposure, and animal species. In the present
study, male Wistar rats were fed between postnatal days 21 and 63 with diets that contained fumonisins
B1 + B2 at concentrations of 1 and 3 mg/kg. The objective of the present study was to evaluate the effects of
fumonisins on food intake, growth, weight gain, serum activity of the alanine aminotransferase and aspartate
aminotransferase enzymes, and quantitative and morphometric parameters of myenteric neurons in the
jejunum that are immunoreactive to HuC/D protein and neuronal nitric oxide synthase enzyme (nNOS). Diets
that contained fumonisins did not signiﬁcantly alter food intake or body and blood parameters. We did not
observe signiﬁcant differences in the neuronal density and proportion of nitrergic neurons but found a signiﬁcant
reduction of cell body areas in both neuronal populations. This study is theﬁrst to report the effects of fumonisins
in the enteric nervous system. The possiblemechanisms bywhich fumonisins impair neuronal development and
the use of the enteric nervous system as a tool for the study of the neurotoxic effects of fumonisins are discussed.
In conclusion, fumonisin-containing food negatively affected the growth of myenteric neurons.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Fumonisins are mycotoxins that are produced by several fungus
species, especially Fusarium verticillioides and Fusarium proliferatum,
which produce large amounts of these mycotoxins and are present in
several places in the world as contaminants in corn plantations (Voss
et al., 2007). Streit et al. (2013) estimated that 50–63% of all grains
produced for livestock feeding in the world are contaminated with
fumonisins with a worldwide average of 0.914 mg/kg. In positive sam-
ples, the average level of fumonisins was 1.689 mg/kg, and the maximal
level was approximately 77.502 mg/kg. Contaminationwithmycotoxins
in grain plantations has attracted economic and scientiﬁc interest
because these plantations arewidely used for livestock and human feed-
ing. Several countries have implemented laws that limit the maximal
levels of fumonisins and other mycotoxins that are allowed in foods forconsideration for publication in
animals are in accordance with
boratory Animals.
a, Km 04, Dois Vizinhos, Paraná,
sa).human and animal consumption. The limits established by law are
generally obtained by extrapolating experimental data, and a revision
of permissible levels may be necessary based on new data that become
available (Voss et al., 1996).
Fumonisins were isolated and chemically characterized for the ﬁrst
time in 1988. Since then, 28 analogs have been described. Fumonisin
B1 (FB1) is the most abundant analog representing 70–80% of the total
amount. Fumonisin B2 (FB2) represents 15–25%, and the remaining
analogs occur in low amounts (Rheeder et al., 2002). Despite almost
30 years of research, the mechanism of action of fumonisins is not yet
fully understood.Wang et al. (1991) reported that FB1 is a potent inhib-
itor of ceramide synthase, a key enzyme in the de novo synthesis and
turnover of complex sphingolipids, such as sphingomyelin and
glycosphingolipids, which participates in the composition of cellular
membranes. In cells exposed to fumonisins, the synthesis of ceramide
is reduced with a consequent decrease in the amount of sphingolipids
and increase in their precursors, sphinganine and sphingosine. In addi-
tion to their structural role in cellular membranes, sphingolipids and
their metabolic precursors participate in cellular signaling (Soriano
et al., 2005). Thus, alterations caused by fumonisins in the metabolism
of sphingolipids impact other metabolic pathways, thereby leading to
alterations in development, morphology, and cell survival (Merril
et al., 1997).
Table 1
Composition of the base diet provided to rats during the experimental period.
Ingredient (%)
Corn 33.63
Soybean meal 33.10
Wheat bran 27.20
Soybean oil 2.30
Calcitic limestone 2.07
Bicalcic phosphate 0.73
Salt (iodized) 0.50
Vitamin premixa 0.10
Mineral premixb 0.35
BHTc 0.02
Dry matter (%)d 93.60
Raw energy (kcal/kg)d 4120.46
Raw protein (%)d 22.37
a Vitamin supplement, composition per kg: 200 mg folic acid; 3000 mg nicotinic acid;
20 mg biotin; 1600 mg calcium pantotenate; 700 mg pyridoxine HCl; 600 mg riboﬂavin;
600 mg thiamin HCl; 4,000,000 UI vitamin A; 2500 mg vitamin B12; 100,000 UI vitamin
D3; 100,000 UI vitamin E; and 75 mg vitamin K1.
b Mineral supplement, composition per kg: 14.26 mg boron; 142.94 g calcium; 44.9 g
chloride; 72.41 mg copper; 28.65 mg chrome; 8.6 g sulfur; 1000 mg iron; 28.72 mg
ﬂuoride; 5.9 g phosphorus; 5.95 mg iodine; 2.85 mg lithium; 14.48 g magnesium;
300 mg manganese; 4.32 mg molybdenum; 14.31 mg nickel; 102.86 g potassium;
4.28 mg selenium; 143.26 mg silicon; 29.38 mg sodium; 2.87 mg vanadium; and
860 mg zinc.
c Botuil hydroxy toluene.
d According to the chemical analysis.
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fumonisins is related to the development of porcine lung edema and
equine leukoencephalomalacia (Waes et al., 2005), which is a disease
characterized by necrosis of the brain hemispheres. In humans, epidemi-
ological studies indicate a relationship between the ingestion of
fumonisins and an increased incidence of defects in neural tubes (Waes
et al., 2005). The intake of fumonisinsmay also be related to neurodegen-
erative diseases, such as multiple sclerosis, Alzheimer's disease, and
Parkinson's disease (Kovačić et al., 2009; Purzycki and Shain, 2010).
Several studies have been conducted with the objective of clarifying
the mechanisms by which fumonisins induce toxicity in the nervous
system (Domijan, 2012). However, until now, such studies have focused
on the effects on the central nervous system and rarely investigated
the effects on the peripheral nervous system. Despite evidence that
fumonisins affect the digestive system (Bouhet and Oswald, 2007)
leading to alterations in intestinal absorption, increased susceptibility
to infections, and alterations in the intestinal immune response, no
study of which we are aware of has investigated the effect of these
mycotoxins on the enteric nervous system, which is responsible for the
intrinsic innervation of this system.
The enteric nervous system is the more complex portion of the
peripheral nervous system. It is indispensable for maintaining homeo-
stasis in the digestive system and an excellent model for the study of
the nervous system as a whole (Anderson et al., 2006). Considering
that exposure to neurotoxic substances during childhood can cause
neurological problems later in development (Kovačić et al., 2009), the
present study evaluated the effects of a fumonisin-contaminated diet
(1 and 3 mg/kg fumonisin) on the myenteric plexus of the jejunum in
developing rats.
2. Material and methods
The Ethical Committee on Animal Experimentation of the
Universidade Estadual de Maringá (protocol no. 044/2010) approved
the procedures in this study that involved the use of animals.
2.1. Animals and experimental design
ThirtymaleWistar rats (Rattus novergicus), whichwere 21 days of age
and with approximately 50 ± 5 g body weight, were used. The animals
were maintained in plastic cages with ﬁve animals per cage under con-
trolled light (12 h/12 h light/dark cycle) and temperature (22 ± 2 °C).
The animals were randomly separated into three experimental
groups: F0 (fed a diet without fumonisins), F1 (fed a diet with 1 mg/kg
fumonisins [FB1 + FB2]), and F3 (fed a diet with 3 mg/kg fumonisins
[FB1 + FB2]). The animals had ad libitum access to food and water.
Each experimental group was composed of 10 animals. Five of the
animals in each group were euthanized 15 days after the experiment
began (36 days old), and the other ﬁve were euthanized 42 days after
the experiment began (63 days old).
2.2. Experimental diets
For the preparation of the base diet (Table 1), corn, wheat bran, and
soybeans were ground in a knife mill with a sieve (0.50 mm diameter
particle size) and mixed by hand with the other ingredients. For the
production of the diets with fumonisins, we added a sterilized culture
medium of the fungus F. verticillioides, strain MRC 826, to the base
diet, which was mixed again and homogenized. The Laboratório de
Análises Micotoxicológicas (LAMIC) of the Universidade Federal de
Santa Maria (UFSM), Rio Grande do Sul, Brazil, provided the culture
medium. The food was then pelleted and dried in an oven with forced
ventilation (55 °C) for 24 h.
Samples of each type of diet were sent to LAMIC for qualitative and
quantitative analyses of fumonisins using liquid chromatography coupled
with sequential mass spectrometry (LC–MS/MS). The analysis of the dietof the F0 group revealed very low levels of FB1 (0.159 mg/kg) and the ab-
sence of FB2. The analysis of the diet of the F1 group revealed amean level
of fumonisins of 0.996 mg/kg (0.729 mg/kg FB1 and 0.267 mg/kg FB2).
The analysis of the diet of the F3 group revealed a mean level of
fumonisins of 2.819 mg/kg (2.100 mg/kg FB1 and 0.719 mg/kg FB2).
The animals' body weight and food intake were measured weekly.
Food intake was evaluated by subtracting the remaining food from the
total food given to the animals. We calculated the average food intake
per 100 g of body weight based on these data. We calculated fumonisin
intake per kg of body weight per day based on this average food intake
and the average fumonisin concentrations in the foods. Lee's index,
which was an indicator of the relationship between size and body
mass (similar to the body mass index in humans), was calculated
using the following formula: [(body weight in g)1/3 / nasoanal distance
in cm] × 1000 (Stephens, 1980).
2.3. Euthanasia and collection of biological samples
Fifteen days after the experiment began, ﬁve animals in each group
were euthanized with an intravenous injection of sodium thiopental
(120 mg/kg of body weight). Blood samples were collected to analyze
the serum activity of the alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) enzymes using standardized commercial kits
(Gold Analisa, Belo Horizonte, Brazil). Forty-two days after the experi-
ment began, the other ﬁve animals in each group underwent the same
procedures for euthanasia, blood collection, and analysis. Additionally,
the small intestine was removed, and its area was calculated by multi-
plying the width by the length. Jejunum samples from each animal
were collected from the proximal portion of the organ and utilized for
the study of myenteric neurons.
2.4. Immunohistochemistry
The jejunum samples were washed with 0.1 M phosphate-buffered
saline (pH 7.4), ﬁlled with ﬁxative (4% paraformaldehyde in 0.1 M
PBS, pH 7.4), tied at the extremities, immersed in the same ﬁxative,
and maintained under refrigeration at 4 °C for 2 h. The extremities
were then opened. The samples were washed twice with 0.1 M PBS
(pH 7.4) and stored under refrigeration at 4 °C in 0.1 M PBS (pH 7.40)
with the addition of 0.08% sodium azide (Sigma-Aldrich, St. Louis, MO,
Table 2
Body parameters and food intake in rats fed for 42 dayswith diets without the addition of
fumonisins (F0) andwith the addition of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins
(F3).
Parameter Experimental group
F0 F1 F3
Initial weight (g) 50.40 ± 6.79 47.60 ± 5.32 50.30 ± 5.20
Final weight (g) 288.90 ± 14.22 268.10 ± 18.63 285.10 ± 10.29
Weight gain (%) 441.4 ± 54.86 476.00 ± 84.48 440.40 ± 57.08
Lee index 295.00 ± 6.58 287.70 ± 6.78 293.50 ± 3.51
Average food intake
(g/100 g of body mass
per week)
75.32 ± 9.37 72.58 ± 8.61 77.28 ± 10.16
n = 5. The ANOVA did not reveal signiﬁcant effects. The data are expressed as mean ±
standard deviation.
Table 3
Serum activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
in rats fed for 15 or 42 days with diets without the addition of fumonisins (F0) or with
the addition of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins (F3).
Group ALT (U/L) AST (U/L)
15 Day treatment
F0 63.00 ± 10.79 105.02 ± 17.98
F1 76.40 ± 21.65 84.80 ± 10.16
F3 79.40 ± 9.07 99.60 ± 23.06
42 Day treatment
F0 50.20 ± 5.72 119.0 ± 39.03
F1 54.40 ± 4.56 120.00 ± 49.79
F3 45.80 ± 1.79 105.80 ± 24.61
n = 5. The ANOVA did not reveal signiﬁcant effects. The data are expressed as mean ±
standard deviation.
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myenteric plexuswere obtained through samplemicrodissection under
a stereomicroscope.
Thewholemountswere subjected to double immunostaining for the
detection of HuC/D protein (Lin et al., 2002) and neuronal nitric oxide
synthase enzyme (nNOS) (Wrozs et al., 1997). The whole mounts
were washed twice with 0.01 M PBS (pH 74) with 0.5% Triton X-100
(Sigma-Aldrich, St. Louis, MO, USA) for 10 min per wash and immersed
for 1 h in a solution that contained 0.01 M PBS (pH 7.4), 0.5% Triton
X-100, 2% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO,
USA), and 10% goat serum to prevent nonspeciﬁc binding. Subsequently,
the tissues were incubated at room temperature with constant shaking
for 48 h in a solution that contained 0.01 M PBS (pH 7.4), 0.5% Triton
X-100, 2% BSA, 2% goat serum, andmouse anti-HuC/D (Life Technologies,
Carlsbad, CA, USA) and rabbit anti-nNOS (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) primary antibodies, which were both diluted at
1:500. The whole mounts were then washed three times with 0.01 M
PBS (pH 7.4) and 0.5% Triton X-100 for 5 min per wash and incubated
for 2 h at room temperature with Alexa Fluor 488 anti-mouse (Life
Technologies, Carlsbad, CA, USA) and Alexa Fluor 546 anti-rabbit (Life
Technologies, Carlsbad, CA, USA) secondary antibodies, which were
both diluted at 1:500 in a solution of 0.01 M PBS (pH 7.4), 0.5% Triton
X-100, 2% BSA, and 2% goat serum. Thewholemountswere thenwashed
with 0.01MPBS (pH 7.4) and placed between lamina and cover slipwith
mounting medium for immunohistochemistry ﬂuorescence, ProLong®
Gold (Life Technologies, Carlsbad, CA, USA).
2.5. Quantitative and morphometric neuronal analysis
Myenteric neurons that were immunoreactive to HuC/D and nNOS
were counted in 32 images (12,48mm2) for each animal in each exper-
imental group. The images were acquired with an Axioskop 2 Plus
(Zeiss)microscope equippedwith an HBO 100 (Zeiss) ﬂuorescence sys-
tem and AxioCam HRc (Zeiss) camera for ﬂuorescent image capture.
The images were captured using an objective lens with 20× magniﬁca-
tion. All of the images were taken from the intermediary region of the
intestinal circumference to avoid interference from natural variations
in neuronal density along the intestinal circumference. The neuronal
quantiﬁcation was performed using the ImageTool 3.0 software
(University of Texas Health Science Center, San Antonio, TX, USA). The
results were used to calculate neuronal density per cm2.
For the morphometric analyses, the areas of the cell body pro-
ﬁles (μm2) of 150 HuC/D-immunoreactive neurons and 150 nNOS-
immunoreactive neurons were measured per animal. The neuronal mea-
surements were performed using the same images that were used for
quantitative analysis using the ImageTool 3.0 software. The results were
used to calculate the average area of cell bodies anddistribution of the fre-
quency as a function of the cell body area in arbitrary intervals of 50 μm2.
2.6. Statistical analysis
The data were analyzed for normality using the Shapiro–Wilk test
and R 2.15.2 software. The means were compared using analysis of
variance (ANOVA) with Tukey's post hoc test for multiple comparisons.
The frequency distributions were analyzed using the χ2 test and Prism
6.0 software (GraphPad, San Diego, CA, USA). The level of signiﬁcance
was 5%, and the results are expressed as mean ± standard deviation.
3. Results
3.1. Body parameters and food intake
No mortality or signs of acute intoxication, such as fur bristling or
drooping, mucosal or tail cyanosis, lethargy, or anorexia, were observed
during the experimental period. Table 2 shows the data for variations of
body parameters and food intake. No signiﬁcant group differences inbody weight gain, Lee's index, or food intake were observed during the
experiment. The average fumonisin consumption was 17.11 ± 2.13,
103.30 ± 12.25, and 311.20 ± 40.89 μg/kg of body weight per day in
the F0, F1, and F3 groups, respectively. The analysis did not reveal signif-
icant differences in serum biochemical parameters (Table 3). The aver-
age areas of the small intestinewere 119.4± 26.04, 100.20± 9.76, and
112.7 ± 14.32 cm2 in the F0, F1, and F3 groups, which were not signif-
icantly different.3.2. Neuronal analysis
3.2.1. Neuronal quantiﬁcation
Double immunostaining revealed that the fumonisin-containingdiet
did not alter the morphological organization of the myenteric plexus,
with the majority of neurons located in the ganglia (Fig. 1). The neuro-
nal counts in an area of 12.48 mm2 per animal were extrapolated to de-
termine neuronal density (Table 4). Because no differences in the
intestinal areas were found (see section 3.1), the use of a correction fac-
tor for neuronal density was unnecessary. No signiﬁcant differences in
neuronal density in the general (HuC/D-immunoreactive) and nitrergic
(nNOS-immunoreactive) populations were observed.3.2.2. Neuronal morphometry
The morphometric analyses revealed that the fumonisin-containing
diets signiﬁcantly reduced the average area of the cellular proﬁle for
both the general population of myenteric neurons and the nitrergic
subpopulation (Table 4, Fig. 1). The data were distributed as frequency
classes at arbitrary intervals of 50 μm2 indicating a range of variation
in the neuronal area. Figs. 2 and 3 present the histograms of the frequency
distributions and statistical results.
Fig. 1. Photomicrographs ofmyenteric ganglia of the jejunum in rats fed a dietwithout addition of fumonisins (F0) or with the addition of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins
(F3). Myenteric ganglia in the F3 group displayed small cell bodies (arrow). 20× objective.
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The 1 and 3 mg/kg fumonisin concentrations in the food used in the
present study are equivalent to food preparations that contain corn in a
proportion of 34% (Table 1) with fumonisin concentrations of 3
and 9 mg/kg. Corn harvests with these levels of contamination are
common in several parts of the world (Rodrigues and Naehrer, 2012;
Yazdanpanah et al., 2006). Thus, the concentrations of fumonisins
used in the present study represent values that are commonly found
in food for livestock and human consumption (Zimmer et al., 2008).
For humans, different feeding habits and socioeconomic conditions
determine the quantity of corn-based food in the diet. In regions
where corn is the base for food, the consumption of a diet rich in corn,
with fumonisin concentrations of approximately 3 mg/kg, has been
suggested to cause high indices of esophageal cancer in humans (van
der Westhuizen et al., 2003). Therefore, various countries have laws
that limit themaximal concentration of fumonisins to 3 mg/kg in prod-
ucts that are destined for human consumption. For some animal species,
laws limit the concentrations of fumonisins in the diet to values that are
less than the concentrations used in the present study. For example, the
United States Food and Drug Administration limits the fumonisin
concentration to 1 mg/kg for rabbits and horses (FDA, 2001).
In the present study, we opted to use 21- to 63-day-old animals,
which are in a developmental phase that is equivalent to late childhood,
adulthood, and the beginning of the animals' reproductive lives (NistiarTable 4
Neuronal density and area of the cellular proﬁle of myenteric neurons of the jejunum in
rats fed for 42 dayswith dietswithout the addition of fumonisins (F0) orwith the addition
of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins (F3).
Groups Neuronal density (neurons/cm2) Area of the cellular proﬁle (μm2)
HuC/D nNOS HuC/D nNOS
F0 13,595 ± 979 3801 ± 306 392.9 ± 146⁎ 482.6 ± 129⁎
F1 14,267 ± 1216 3814 ± 325 383.1 ± 141 436.1 ± 138⁎
F3 14,215 ± 782 4160 ± 432 368.8 ± 132⁎ 411.3 ± 125⁎
n = 5.
⁎ p b 0.05, ANOVA followed by Tukey's test. The data are expressed as mean ± standard
deviation.et al., 2012). These are critical periods for development, especially for
the nervous system. Childhood is also a period of increased intake of
corn-based foods. Thus, laws that limit mycotoxins are more exigent
for foods that are destined for children. For example, the European
Union and Brazil limit the amount of fumonisins to 0.2 mg/kg in foods
for children (BRASIL, 2011; EC, 2007).
The intake of fumonisins in all of the experimental groups in the
present study exceeded the limit of 2 μg/kg of body weight per day
that is recommended for humans by the United Nations Organization
(FAO/WHO, 2011). In the F3 group, the average intake of fumonisins
over the course of the experiment was 311.20 ± 40.89 μg/kg of body
weight per day, a value close to the consumption by human populations
with high levels of fumonisins, such as in the rural areas in South Africa
(Marasas, 2001). Notably, the diets that contained fumonisin levels of 1
and 3 mg/kg neither affected food intake nor impaired the animals'
growth. The rats in the F1 and F3 groups did not present a reduction
of weight gain or the Lee's index. This result is consistent with
Gelderblom et al. (2001), who reported that rats fed for up to 14 months
with a diet that contained FB1 at levels of 1, 10, and 25 mg/kg did not
present a reduction of weight gain or food intake. Gelderblom et al.
(1994) observed a reduction of food intake in rats fed diets that
contained 250, 500, and 750 mg/kg FB1 compared with animals that
were fed a diet without fumonisins. However, this reduction was only
seen in the ﬁrst 2 weeks of the experiment. After this time, food intake
was equivalent, and no signiﬁcant group differences in the body mass
were observed at the end of the experiment.
In all of the experimental groups, food intake as a proportion of body
mass peaked during the ﬁrst three weeks of the experiment, which
corresponds to more rapid animal growth. After this time, food intake
decreased until the end of the experiment. Thus, food intake in the
third week of the experiment was an average of 40% higher than food
intake in the sixth week of the experiment. The increase in food intake
relative to body mass during the ﬁrst weeks of the experiment resulted
in an increase in the ingestion of fumonisins as a proportion of body
mass. Consequently, in developing animals, fumonisin intoxication
develops in two phases: an initial phase with a proportionally higher
intake of the toxin and a subsequent phase with a gradual reduction
of toxin intake as a proportion of body mass.
97F.C. Sousa et al. / Autonomic Neuroscience: Basic and Clinical 185 (2014) 93–99To evaluate whether an increase in the ingestion of fumonisins during
the initial period of the experiment could cause hepatic lesions in the an-
imals,ﬁve animals in each groupwere euthanized 15days after the exper-
iment began, and blood samples were analyzed to determine the AST and
the ALT activity. Forty-two days after the experiment began, the same
blood tests were performed in the remaining ﬁve animals in each experi-
mental group (Table 3). We did not observe signiﬁcant differences in ALT
or AST after 15 or 42 days of being fed the fumonisin-containing diet.
Gelderblom et al. (2001) observed hepatic lesions, apoptosis, the prolifer-
ation of ductule epithelial cells and ﬁbrosis, in rats chronically treated for
24 months with 1, 10, and 25 mg/kg FB1 in the diet. Only AST was
increased and only at FB1 doses of 10 and 25 mg/kg. Thus, the lower
doses and shorter time of administration in the present study justiﬁed
the absence of differences in the activity of the AST and ALT enzymes.
During the entire experimental period, we did not observe symptoms
of gastrointestinal problems, such as diarrhea. However,mild signs of gas-
trointestinal problems aredifﬁcult to evaluate in animals. In humans, Bhat
et al. (1997) reported an outbreak of fumonisin intoxication in India that
was caused by the consumption of corn and sorghum contaminatedwith
fumonisins, which was characterized by intestinal symptoms, including
diarrhea, abdominal pain, and borborygmus. The relationship between
fumonisin consumption and the development of esophageal cancer in
humans has been studied since investigations of the incidence of this
type of cancer in the Transkei region of South Africa led to the discovery
of fumonisins (Rheeder et al., 1992). In the present study, we did not
observe anymacroscopic differences, such as tumors, in the entire gastro-
intestinal tract, with no signiﬁcant difference in the size or mass of the
small intestine in the F1 and F3 groups compared with the F0 group.
According to Grenier andApplegate (2013), although the intestine is
the principal route ofmycotoxin absorption, the literature on the effects
of mycotoxins in intestinal physiology is scarce. Bouhet and Oswald
(2007) reported that fumonisins impair intestinal absorption, increase
the susceptibility to infections, and alter the intestinal immune re-
sponse. Although several studies have investigated the neurotoxic
effects of fumonisins, they focused on the central nervous system,
with no information on the effects of fumonisins on the enteric
nervous system,which represents the principalmechanism of neuronal
control of gastrointestinal tract function.
Fig. 1 shows that the intake of foods with fumonisins between 21
and 63 days of life at the doses used herein did not alter the typical
morphological arrangement of the myenteric plexus, and the neurons
maintained their ganglion localization. Table 4 illustrates that the
consumption of fumonisin-containing diets in the F1 and F3 groups
did not lead to signiﬁcant alterations in the density of the general pop-
ulation of myenteric neurons, HuC/D-immunoreactive, or the popula-
tion of nitrergic neurons, nNOS-immunoreactive. No alterations were
found in the proportion of nitrergic neurons compared with the total
neuronal population. The nitrergic population represented an averageFig. 2.Histogram of the frequency distribution as a function of the size of HuC/D-immunoreactiv
of fumonisins (F0) or with the addition of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins (F3of 28% of the neurons. Considering that myenteric neurons are a non-
renewable cellular population (Souza et al., 1993), the present results
demonstrate that a diet that contains fumonisins at doses of 1 and
3 mg/kg did not cause neuronal death in the myenteric plexus in rats.
Several studies have investigated the effects of fumonisins on neu-
ron survival. Generally, however, these studies used in vitro approaches,
unnatural forms of inoculation, or very high doses that are not usually
found in real situations. Stockmann-Juvala et al. (2004) studied the via-
bility of human SH-SY5Y neuroblastoma cells and mouse GT1-7 hypo-
thalamic cells in cultures that contained FB1 at doses of 1, 10, and
100 μM for 48, 72, and 144 h and observed a reduction of cell viability
only at the highest dose. Osuchowski and Sharma (2005) exposed
N2A neuroblastoma cells and BALB/c mouse cortical neurons to doses
of FB1 up to 50 μM for periods of up to 4 days for N2A cells and 8 days
for cortical neurons and did not observe a reduction of cell viability.
Osuchowski et al. (2005) exposed female mice to 10 and 100 μg FB1
for 7 days subcutaneously or by direct injection in the brain ventricles
and observed brain cortex neurodegeneration with the highest dose.
Given the discrepant results in the literature, Domijan (2012) concluded
that the cytotoxic effects of fumonisins in the cells of thenervous system
tissue are determined by the duration of exposure, concentration, cell
type, brain region, and animal species.
Althoughwe did not observe a reduction of neuronal density, we did
observe (Table 4, Figs. 2 and 3) that the fumonisin-containing diet af-
fected the size of myenteric neurons in both the general and nitrergic
populations, with a signiﬁcant reduction of the average cellular proﬁle
in the F3 group compared with the F0 group for the general population
and a signiﬁcant reduction of the nitrergic population in the F1 and F3
groups compared with the F0 group. Despite being reduced in size,
nitrergic neurons kept their typical morphology of Dogiel type I
neurons.
Myenteric neurons exhibit large variability in size and shape, and the
use of the average number of myenteric neurons does not adequately
represent the possible variations in the size of these neurons. Therefore,
the neuronalmeasurement datawere converted into frequency distribu-
tionswith classes at arbitrary intervals of 50 μm2, which are presented as
histograms in Figs. 2 and 3. This analysis indicated a higher concentration
of neurons in the smaller cell proﬁle class in the F1 and F3 groups com-
pared with the F0 group, reﬂected by a leftward shift of the histogram.
Myenteric neurons undergo intense neuroplasticity during the
organism's growth and aging. According to Marese et al. (2007), the
length of the small intestine increases by approximately 400% between
21 and 60 days of age, and the neuronal density of themyenteric plexus
decreases by 50%. However, the average size of neurons increases by
53%. According to these authors, this process extends throughout life
in a neuroplastic mechanism whereby hypertrophy of the remaining
neurons occurs concomitantly with neuronal death to warrant the in-
nervation of the gastrointestinal tract for functional maintenance. Thee neurons in the intermediary region of the jejunum in rats fed a diet without the addition
). The differences in the distributions were not signiﬁcant (p N 0.05; χ2 test).
Fig. 3.Histogramof the frequency distribution as a function of the size of nNOS-immunoreactive neurons in the intermediary region of the jejunum in rats fed a dietwithout the addition of
fumonisins (F0) or with the addition of 1 mg/kg fumonisins (F1) or 3 mg/kg fumonisins (F3). The differences in the distributions were statistically signiﬁcant (p b 0.05; χ2 test).
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the cellular proﬁle and an increase in the number of small neurons in
the myenteric plexus in rats that were fed a diet that contained
fumonisins at doses of 1 and 3 mg/kg, indicating that fumonisin intake
negatively inﬂuences neuroplastic mechanisms in the small intestine
in rats between 21 and 63 days of age.
Because the size of enteric neurons is directly related to the size of
their area of innervation, the observation that fumonisin reduced the
neuronal area without affecting the size of the intestine leads to the hy-
pothesis that this mycotoxin can impair the ability of neurons to control
their innervation targets, thus impairing the function of the gastrointes-
tinal tract. Heuckeroth et al. (1999) found results in neurturin growth
factor knockout mice that were similar to those observed in the present
study (i.e., a reduction of the enteric neuronal area, no signiﬁcant reduc-
tion of thenumber of neurons, andmaintenance of the size of the organs
of the gastrointestinal tract). These animals displayed a reduction of the
release of neurotransmitters and decreased gastrointestinal motility. In
the present study, no signs of gastrointestinal distress were observed in
the animals, but further studies with higher doses of fumonisins and di-
rect analyses of neurotransmitter systems may reveal alterations in the
function of the gastrointestinal tract.
The present results indicated that a fumonisin-containing diet affect-
ed the growth process of myenteric neurons, which is consistent with
several studies of the effect of these mycotoxins on the development
of neurons in the central nervous system. Kwon et al. (1997) gave
Sprague–Dawley rats subcutaneous injections of FB1 at doses of 0.4
and 0.8 mg/kg between postnatal days 3 and 12 and found a signiﬁcant
reduction ofmyelination in the corpus callosumand diencephalon, con-
cluding that the process of brain myelination is affected by fumonisins.
Harel and Futerman (1993) collected hypothalamic neurons from
embryonic day 18 Wistar rats and maintained them in culture with
the addition of 10 μM FB1. They found an intense blockade of axonal
growth. Schwarz and Futerman (1998) utilized methodology that was
similar to Harel and Futerman (1993) but added 50 or 200 μM FB1 to
the culture medium. They observed a 25% reduction of the speed of
dendrite growth and an intense reduction of dendrite extension.
The mechanisms by which fumonisins alter survival, development,
and the morphology of neuronal cells are not yet fully understood.
The only known binding site for fumonisins is ceramide synthase. This
enzyme catalyzes a key reaction in the de novo pathway of sphingolipid
synthesis and also exerts actions in the turnover pathway of complex
membrane sphingolipids. Fumonisins cause reversible inhibition
of ceramide synthase (Wang et al., 1991). Utilizing an in vitro ap-
proach, Merril et al. (1993) tested and conﬁrmed the hypothesis
that fumonisins block the synthesis of sphingolipids in neurons.
The inhibition of ceramide synthase reduced the amount of membrane
sphingolipids, such as sphingomyelin and glycosphingolipids, andincreased the concentrations of sphinganine, a precursor in the de
novo pathway, and sphingosine, an intermediate in the turnover path-
way (Soriano et al., 2005). In addition to their role as structural lipids
in the cell membrane, sphingolipids and various precursors and inter-
mediates of their biochemical pathways, such as ceramide, sphingosine,
sphinganine, and their phosphorylated derivatives, act as cellular mes-
sengers that trigger several processes that affect neuronal development,
morphology, function, and survival (Merrill et al., 1997). Thus, some au-
thors have attributed the effects of fumonisins on the nervous system to
the depletion of complex sphingolipids in neuronal membranes (Harel
and Futerman, 1993). Another hypothesis involves the accumulation
of bioactive precursors and intermediates (Colombaioni and Garcia-
Gil, 2004). Other evidence suggests that the effects of fumonisins
may be mediated by immunological alterations (Osuchowski et al.,
2005), an anti-nutritional effect (Carratù et al., 2003), oxidative stress
(Stockmann-Juvala et al., 2004), and mitochondrial dysfunction
(Domijan and Abramov, 2011).
Future studieswill likely expand and clarify the effects of fumonisins
on thenervous system. These studiesmay lead to revisions of laws relat-
ed to the maximum tolerable limits of mycotoxin exposure and new
discoveries in the physiology of the nervous system. Because of the
relatively simple morphologic arrangement of the enteric system, its
large biochemical complexity, its functional importance, its easy acces-
sibility, and the availability of several techniques for neuronal assess-
ment, the enteric nervous system is a valuable tool in the study of the
effects of mycotoxins on the nervous system in general.
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